25/09/2018 (Agence Europe) – The European Medicines Agency warned on 24 September that Brexit could disrupt access to 39 medicines (25 for human beings and 14 for animals) that have received a centralised marketing permit. In July, it estimated the number would be 108 (of the 694 products with centralised authorisation). Under EU law, the marketing authorisation holder, the QPPV (person qualified for pharmacovigilance), the PSMF (permanent pharmacovigilance system file) and certain manufacturing sites need to be based in the European Economic Area (EEA) in order for a company to be able to market a medicine in the EU. In a press release, the agency says that for each of the 39 remaining products, the EMA is looking at how to minimise breakdowns in supply and their impact on public health. (SPj)